Streetbeat News

Products Services

LTRN

Lantern Pharma (NASDAQ:LTRN) announced positive preliminary results from its Phase 2 HARMONIC clinical trial for never smokers with advanced NSCLC. The trial showed an 86% clinical benefit rate in the initial patient cohort, with no additional safety concerns. LP-300, combined with chemotherapy, demonstrated promising efficacy regardless of prior TKI treatments.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:01 pm

BNTX

GMAB

MRNA

PFE

BioNTech reported a significant Q2 loss due to lower demand for its COVID-19 vaccine and increased R&D spending on new cancer products. The company missed earnings and sales expectations, with a net loss of 807.8 million euros. BioNTech's partner, Pfizer, raised its 2024 guidance, while Moderna lowered its sales guidance. Genmab will take over the development of acasunlimab from BioNTech.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 11:59 am

ZVRA

The FDA’s Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted in favor of Zevra Therapeutics' (NASDAQ:ZVRA) arimoclomol for treating Niemann-Pick disease type C. William Blair increased the probability of success for arimoclomol to 90% and highlighted Zevra's balanced portfolio. Zevra's stock rose 16.7% in premarket trading.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 11:59 am

AAPL

BRK-A

BTCUSD

NVDA

QQQ

SPY

The stock market is set to open sharply lower on Monday due to negative sentiment from last week. Nasdaq 100 futures are down over 4%, and the VIX has spiked over 100%. Berkshire Hathaway has trimmed its equity portfolio, including selling nearly half of its Apple shares. Tech stocks, particularly Nvidia, are showing notable weakness. Bitcoin has also plunged over 15%. The global sell-off is driven by recession fears and the unwinding of yen carry trades.

Portfolio Pulse from Shanthi Rexaline

August 05, 2024 | 11:51 am

DCGO

DocGo has announced the launch of a mobile X-ray program in partnership with MinXray, aiming to enhance its healthcare services.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:39 am

ALZN

Alzamend Neuro shares are trading higher following the announcement of a partnership with Massachusetts General Hospital for a Phase II trial of AL001.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:37 am

REKR

Rekor Systems, Inc. (NASDAQ:REKR) has launched its Strategic Corridor Monitoring project, funded by a $1.5M federal and state grant. The project will deploy AI-powered sensors to provide real-time traffic insights for the Maryland Department of Transportation State Highway Administration (MDOT).

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:37 am

MDWD

MediWound Ltd. (NASDAQ:MDWD) announced positive results from the NEXT Protocol for NexoBrid in burn treatment, showing high efficacy and safety. The study reaffirmed NexoBrid's benefits in managing severe burns, reducing the need for surgical interventions, and enhancing patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:36 am

IXHL

Incannex Healthcare Inc. (NASDAQ: IXHL) has received FDA approval to conduct a Phase 2 clinical trial for its psilocybin pharmaceutical formulation, PSX-001, in patients with generalized anxiety disorder in the US and UK. The trial, PsiGAD2, will involve 94 patients and aims to measure changes in anxiety levels using the HAM-A score.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:34 am

LNG

Cheniere Energy (NYSE:LNG) has signed a 20-year LNG sale and purchase agreement with Galp Trading S.A., a subsidiary of Galp Energia. Galp will purchase 0.5 million tonnes of LNG annually from Cheniere starting in the early 2030s, contingent on the completion of the Sabine Pass Liquefaction Expansion Project.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:33 am